GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Gilead Sciences Inc.
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. Its stock price reflects both the stable revenues from these franchises and its efforts to diversify into oncology to ensure future growth.
Share prices of companies in the market segment - Pharma virus
Gilead is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C, as well as its growing oncology segment. We classify it as part of the Pharma Virus sector, and the chart below reflects the dynamics of the entire industry.
Broad Market Index - GURU.Markets
Gilead Sciences is a biopharmaceutical company known for its breakthrough treatments for HIV and hepatitis C. Its significant market capitalization earns it a prominent place in the GURU.Markets index. The chart below represents the entire market. See how Gilead's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
GILD - Daily change in the company's share price Gilead Sciences Inc.
For Gilead Sciences, known for its HIV drugs, daily price changes are a measure of its response to new research and patent announcements. While the graph of these fluctuations is unspectacular, it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma virus
Gilead Sciences, Inc. is a leader in antiviral drug development. This chart illustrates the high volatility of the biotech sector. Comparing it to GILD's performance helps understand how its HIV and hepatitis franchises, as well as its oncology business, impact its stability.
Daily change in the price of a broad market stock, index - GURU.Markets
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. The biotech sector is known for its high volatility. The chart below shows average daily fluctuations in the industry, allowing one to assess how Gilead's performance aligns with overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Gilead Sciences Inc.
Gilead Sciences, a leader in the treatment of HIV and liver diseases, has been actively expanding its oncology portfolio over the past year. The stock price movement shown in the chart reflects the market's assessment of this diversification strategy and the potential of new drugs.
Annual dynamics of market capitalization of the market segment - Pharma virus
Gilead Sciences, Inc. is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. Its future growth depends on the success of new developments, particularly in oncology. The chart shows how the market views its research potential compared to other biotech players.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gilead Sciences is a biopharmaceutical company known for its breakthroughs in the treatment of HIV and hepatitis C. Its performance is determined by the life cycle of its key drugs and its success in developing new ones. For investors, this is a story about how scientific innovation can create enormous value, but also about the risks associated with patent expiration.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Gilead Sciences Inc.
The value of Gilead Sciences, a biotech focused on antiviral drugs, is highly dependent on its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials in HIV and oncology, as well as sales data for its existing blockbuster drugs, which face patent competition.
Monthly dynamics of market capitalization of the market segment - Pharma virus
This chart reflects the dynamics of the biotech sector. For Gilead, with its strong position in HIV and viral hepatitis treatments, this is the backdrop. It shows how the company, while managing its mature portfolio, is seeking new growth drivers, particularly in oncology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
This chart reflects the dynamics of the entire stock market. For Gilead, a mature biotech company, this is the backdrop. It demonstrates how resilient its business, which depends on successful development of new drugs and lifecycle management of existing ones, has been to overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Gilead Sciences Inc.
Gilead Sciences, a biopharmaceutical company known for its breakthroughs in HIV and hepatitis C treatments, sees its stock price react weekly to news from its oncology division and the results of clinical trials of new drugs. The chart reflects the company's efforts to diversify its revenue sources.
Weekly dynamics of market capitalization of the market segment - Pharma virus
Gilead Sciences, known for its HIV drugs, has been attempting to diversify into oncology in recent years. Investors compare its performance with the biotech sector to assess the success of this transformation. This chart shows whether the company is returning to superior growth through new developments or whether it is lagging behind its more innovative competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Gilead Sciences is a biotech company known for its HIV and hepatitis C treatments. After years of success, the company is seeking new growth opportunities. The chart below shows how this uncertainty and competition are impacting its stock price volatility relative to the market.
Market capitalization of the company, segment and market as a whole
GILD - Market capitalization of the company Gilead Sciences Inc.
Gilead Sciences' market capitalization is a story of ups and downs driven by pharmaceutical breakthroughs. The chart shows a huge surge following the success of its hepatitis C drugs, followed by a decline as the market saturated. Its current valuation reflects its strong position in HIV treatment and its efforts to find new blockbusters, making its chart an interesting biotech case study.
GILD - Share of the company's market capitalization Gilead Sciences Inc. within the market segment - Pharma virus
Gilead Sciences is a biotech leader, particularly known for its dominance in the HIV drug market. Its significant market share reflects its decades of research and ability to develop highly effective treatments that have transformed the lives of millions of patients.
Market capitalization of the market segment - Pharma virus
Here's a chart showing the biotech sector's market capitalization, and Gilead Sciences is its leader in antiviral drugs. The company changed the world by creating treatments for HIV and hepatitis C. The dynamics of this market reflect humanity's ongoing battle against viruses, and Gilead is at the forefront of this battle.
Market capitalization of all companies included in a broad market index - GURU.Markets
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for viral diseases such as HIV and hepatitis C. Its market capitalization reflects the impact of its drugs on global health. The chart below shows the impact of scientific progress in the fight against disease.
Book value capitalization of the company, segment and market as a whole
GILD - Book value capitalization of the company Gilead Sciences Inc.
Gilead Sciences's core assets are its R&D centers and manufacturing facilities, which have enabled the creation of revolutionary drugs for the treatment of HIV and hepatitis C. Its book value reflects this scientific and manufacturing prowess. Its chart is a complex story of booms following blockbuster releases and periods of searching for new breakthrough technologies.
GILD - Share of the company's book capitalization Gilead Sciences Inc. within the market segment - Pharma virus
Danaher is a unique conglomerate focused on science and technology, with a vast manufacturing base. The chart shows its total stake in physical assets across various sectors, from diagnostic equipment manufacturing plants to biopharma component manufacturers.
Market segment balance sheet capitalization - Pharma virus
Gilead Sciences is a biotech company known for its antiviral drugs. Pharmaceuticals, as the chart shows, are capital-intensive. Gilead invests billions in R&D but also owns factories to manufacture its blockbusters on a global scale.
Book value of all companies included in the broad market index - GURU.Markets
Gilead Sciences, Inc. is a leader in antiviral drugs, transforming the treatment of HIV and hepatitis C. Its book value reflects its manufacturing capacity and, more importantly, its intellectual property in life-saving medicines, the result of decades of R&D.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Gilead Sciences Inc.
Gilead Sciences, Inc. is a biotech company known for its breakthroughs in HIV treatment. Its premium reflects not only its current sales but also investors' faith in its scientific platform, which is capable of producing new blockbusters, as it did with its hepatitis C drugs.
Market to book capitalization ratio in a market segment - Pharma virus
Gilead Sciences is a biotech company known for its breakthrough treatments for HIV and hepatitis C. Its valuation depends on the success of its current franchises and its ability to develop new drugs. This chart shows how the market values its scientific potential and product portfolio, which determines its value beyond its tangible assets.
Market to book capitalization ratio for the market as a whole
Gilead Sciences is a biopharmaceutical company best known for its breakthrough treatments for HIV and hepatitis C. Compared to average market valuations, as shown in this chart, its valuation reflects a balance between stable revenues from existing franchises and the need to expand its portfolio with new, successful developments.
Debts of the company, segment and market as a whole
GILD - Company debts Gilead Sciences Inc.
For Gilead Sciences, a biotech company known for its HIV and hepatitis C treatments, debt has become a diversification tool. Following the success of its blockbusters, the company used leverage to make major acquisitions (Kite Pharma, Immunomedics) in the oncology field. This chart shows its efforts to find new growth opportunities through M&A.
Market segment debts - Pharma virus
Gilead Sciences is a biotech company known for its breakthrough drugs for the treatment of HIV and hepatitis C. Following the success of these drugs, the company faced the challenge of expanding its pipeline, which led to major debt-financed acquisitions. This chart shows how Gilead's debt profile has changed as it seeks new growth opportunities.
Market debt in general
Gilead Sciences is a biopharmaceutical company that has made breakthroughs in the treatment of HIV and hepatitis C. Its financial strength allows it to invest in risky research and make large acquisitions in promising areas such as oncology. This total debt chart helps assess how Gilead is using its capital to transform its portfolio against the backdrop of overall market conditions.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Gilead Sciences Inc.
Gilead Sciences is a biotech company known for its breakthrough drugs for the treatment of HIV and hepatitis C. This chart shows how the company uses debt to diversify its business, especially after revenue from hepatitis drugs declined. Major acquisitions in oncology were financed with debt, increasing risks.
Market segment debt to market segment book capitalization - Pharma virus
Gilead Sciences is a biopharmaceutical company best known for its breakthrough drugs for the treatment of HIV and hepatitis C. Its future depends on the success of its new developments. This chart shows how Gilead finances its research, aligning its debt policy with the overall financial picture of the pharmaceutical sector.
Debt to book value of all companies in the market
Gilead Sciences, known for its breakthrough drugs, has a strong balance sheet. This chart compares its financial position to the broader market. It shows that this mature biotech giant's debt load is significantly lower than the average company in the economy, highlighting its financial strength and ability to execute large transactions.
P/E of the company, segment and market as a whole
P/E - Gilead Sciences Inc.
This chart for Gilead Sciences, a biotech company known for its HIV drugs, shows a valuation driven by innovation. The company's P/E reflects both the stable revenues from its HIV franchise and investor expectations for new breakthroughs, such as in oncology, that are essential for future growth.
P/E of the market segment - Pharma virus
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. The company is actively developing its oncology portfolio. This chart shows the average valuation for the biotech sector, allowing investors to gauge the market's perception of Gilead's prospects for new developments following the success of its past blockbusters.
P/E of the market as a whole
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. Its valuation depends on the life cycle of its current blockbusters and the success of its research programs in new areas, such as oncology. Unlike cyclical companies, its fate is less determined by the overall market backdrop, as illustrated by this chart.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Gilead Sciences Inc.
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. This chart reflects investor expectations for its ability to find new sources of growth. The valuation depends on sales forecasts in virology and oncology, as well as the success of its research pipeline in developing new drugs.
%20P%2FE%20Gilead%20Sciences%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Gilead-Sciences-Inc.&v=1772676738683 "Chart of the company's future (projected) P/E Gilead Sciences Inc.")
Future (projected) P/E of the market segment - Pharma virus
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. The company is currently actively developing its oncology pipeline. This chart is a market assessment of its ability to find new growth opportunities. It compares its profit forecasts with the sector, demonstrating how much investors believe in its new developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772676738725 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. Its future depends on the success of scientific research and the launch of new drugs. While this chart shows general sentiment, news about clinical trials remains key for Gilead, as they could change its trajectory at any moment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772676738755 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Gilead Sciences Inc.
Gilead Sciences, Inc. is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. Its profits are heavily dependent on the life cycle of these franchises and the success of new drug development, including in oncology. This chart illustrates how medical innovations translate into cash flow and the importance of finding new hits.
Profit of companies in the market segment - Pharma virus
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. Its history demonstrates how scientific innovation can not only save lives but also generate enormous profits. The success of its research programs is a key factor in determining the overall growth and profitability of the biotech sector.
Overall market profit
Gilead Sciences is a biopharmaceutical company focused on developing innovative drugs to treat life-threatening diseases such as HIV, viral hepatitis, and cancer. The company's breakthroughs in HIV treatment have transformed a fatal diagnosis into a chronic condition. Gilead's success demonstrates how science can create enormous social and economic value.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Gilead Sciences Inc.
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. This chart reflects market expectations for its current portfolio, as well as its success in oncology, where the company is actively investing to diversify and secure future growth.
%20profit%20of%20the%20company%20Gilead%20Sciences%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Gilead-Sciences-Inc.&v=1772676738902 "Graph of future (projected) profit of the company Gilead Sciences Inc.")
Future (predicted) profit of companies in the market segment - Pharma virus
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. The data on the chart shows profit forecasts for the entire pharmaceutical industry. This allows us to assess how the company is seeking to diversify its business by entering oncology and how this relates to overall trends in the sector.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772676738909 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
The dynamics in this chart reflect expectations for a biopharmaceutical company focused on treating viral diseases. Gilead Sciences' profit forecast depends on sales of its HIV and hepatitis drugs, as well as progress in developing new drugs, including in oncology. Generic competition is a constant risk.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772676738967 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Gilead Sciences Inc.
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. This chart shows how investors value its revenue after the peak of hepatitis drug sales. The multiple reflects the balance between the stable HIV business and the search for new sources of growth, particularly in oncology.
P/S market segment - Pharma virus
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. It is also actively developing its oncology business. This metric reflects the average revenue estimate in the biotech sector. It provides an insight into how investors perceive Gilead's product portfolio and its ability to create new blockbusters.
P/S of the market as a whole
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. The company is currently actively developing its oncology pipeline. This chart, showing Gilead's average revenue estimate, helps understand how the market views its ability to diversify revenue beyond its traditional franchises.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Gilead Sciences Inc.
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. The company is currently actively developing its oncology pipeline. This chart shows how investors estimate future revenue, taking into account the life cycle of its existing blockbusters and the potential of new oncology drugs.
%20P%2FS%20Gilead%20Sciences%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Gilead-Sciences-Inc.&v=1772676739113 "The graph of the company's future (projected) P/S Gilead Sciences Inc.")
Future (projected) P/S of the market segment - Pharma virus
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. This chart shows how the market values its current product portfolio and R&D. Do investors believe the company can replicate its past successes and find new blockbusters, or does its valuation reflect the maturity of its current franchises?
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772676739156 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
Gilead Sciences is a biopharmaceutical company known for its breakthrough treatments for HIV and viral hepatitis. Its scientific developments and commercial success have a significant impact on the healthcare sector. Expectations for Gilead's new drugs, such as those in oncology, support the overall positive outlook, illustrated by this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772676739183 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Gilead Sciences Inc.
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. Its revenue is directly dependent on the success of these franchises and the development of new drugs. This chart shows the commercial performance of its product portfolio and the demand for innovative antiviral agents.
Sales of companies in the market segment - Pharma virus
Gilead Sciences is a biopharmaceutical company known for its breakthrough treatments for HIV and hepatitis C. Its focus is on antivirals and cell therapy. This chart shows total pharmaceutical sales, providing an overview of the market in which Gilead is solving some of the most complex healthcare problems.
Overall market sales
Gilead Sciences is a biopharmaceutical company focused on developing innovative medicines, particularly in the field of viral diseases such as HIV and hepatitis C. The company's success is based on scientific breakthroughs. This overall economic activity chart is indirectly important for Gilead: it impacts government healthcare programs, which are major purchasers of its drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Gilead Sciences Inc.
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. Its future revenue currently depends on the sustainability of its HIV franchise and success in oncology. This chart shows how analysts assess the life cycle of the company's key drugs and the potential of its new developments, particularly in cancer treatment.
%20sales%20of%20the%20company%20Gilead%20Sciences%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Gilead-Sciences-Inc.&v=1772676739250 "Schedule of future (projected) sales of the company Gilead Sciences Inc.")
Future (projected) sales of companies in the market segment - Pharma virus
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and viral hepatitis. This chart displays projected revenues for the entire pharmaceutical sector. It provides insight into overall industry trends, which provides important context for assessing the potential of Gilead's current and future virology and oncology drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772676739251 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Gilead Sciences is a biopharmaceutical company known for its breakthrough treatments for HIV and hepatitis C. Demand for these medications is stable, as they are vital. However, this trend, reflecting the overall economic situation, impacts government healthcare budgets, which finance the purchase of these medications, especially in less developed countries, which is essential for Gilead's global growth.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772676739255 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Gilead Sciences Inc.
Gilead Sciences is a biopharmaceutical company that has made breakthroughs in the treatment of HIV and hepatitis C. This chart tells the story of the ups and downs associated with the launch of revolutionary drugs, followed by the declines when the market becomes saturated or competitors emerge. The company's performance is directly dependent on the success of its scientific research.
Market segment marginality - Pharma virus
Gilead Sciences is a biopharmaceutical company best known for its breakthrough treatments for HIV and hepatitis C. Its business model is based on scientific research and the development of innovative drugs. This chart shows how leadership in key therapeutic areas and proprietary blockbusters contribute to its high profitability compared to the sector.
Market marginality as a whole
Gilead Sciences is a biopharmaceutical company that has made breakthroughs in the treatment of HIV and hepatitis C. This chart shows overall profitability. It illustrates both the ups and downs of biotech. Having created revolutionary drugs, the company has generated superprofits, but now faces the challenge of finding new blockbusters to maintain growth and profitability.
Employees in the company, segment and market as a whole
Number of employees in the company Gilead Sciences Inc.
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. This chart shows the team's scientists and commercial specialists. Headcount dynamics can reflect both the life cycles of key products and strategic acquisitions to enter new therapeutic areas, such as oncology.
Share of the company's employees Gilead Sciences Inc. within the market segment - Pharma virus
This figure demonstrates Gilead Sciences' focus in the pharmaceutical industry. Its share of employees in the sector, particularly in virology, reflects its historical leadership in developing drugs to treat HIV and hepatitis C. This team of scientists revolutionized the treatment of these diseases, turning deadly diagnoses into manageable conditions.
Number of employees in the market segment - Pharma virus
Gilead Sciences is a biopharmaceutical company known for its breakthrough treatments for HIV and hepatitis C. Its success is based on bold scientific research and a willingness to invest in complex projects. This chart illustrates the research-intensive nature of the pharmaceutical industry, where Gilead occupies a unique niche, solving some of the most complex healthcare problems.
Number of employees in the market as a whole
Gilead Sciences is a biotech company known for its revolutionary virology drugs (HIV, Hepatitis C), and has recently been actively developing its oncology pipeline. This graph reflects the economic base that funds healthcare. Stable employment means more people have insurance that covers these innovative and expensive drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Gilead Sciences Inc. (GILD)
Gilead Sciences is a biopharmaceutical company known for its breakthrough treatments for HIV and hepatitis C. Its astronomically high per-employee ratio reflects the immense value of its intellectual property and its ability to create drugs that change the standard of care.
%20of%20the%20company%20Gilead%20Sciences%20Inc.%20(GILD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Gilead-Sciences-Inc.-GILD&v=1772676739326 "Chart of market capitalization per employee (in thousands of dollars) of the company Gilead Sciences Inc. (GILD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Gilead Sciences built its reputation on revolutionary antiviral drugs (HIV, Hepatitis C). Its value lies in its R&D labs. This chart shows the high market value the market places on each employee, betting that their scientific pipeline will produce the next blockbuster.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772676739328 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Gilead Sciences is a biotech company known for its breakthrough drugs for the treatment of HIV and hepatitis C. The high market capitalization per employee, visible in this chart, is the result of a focus on innovative R&D. The company's value is captured in its patents, which generate billions of dollars in revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772676739330 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Gilead Sciences Inc. (GILD)
Gilead Sciences is a biotech company that revolutionized the treatment of HIV and hepatitis C (Sovaldi). This chart illustrates what a true R&D breakthrough is. When Sovaldi entered the market, profits per employee skyrocketed, as a single course of the drug cost tens of thousands of dollars. Now, this trend reflects the search for new blockbusters.
%20Chart%20Gilead%20Sciences%20Inc.%20(GILD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Gilead-Sciences-Inc.-GILD&v=1772676739335 "Company Profit Per Employee (in thousands of dollars) Chart Gilead Sciences Inc. (GILD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Gilead Sciences is a biotech company (HIV, Hepatitis C). This chart shows the average for the pharmaceutical industry. This sector is a "blockbuster business." The benchmark for employee profitability is high, as a single breakthrough drug (like Sovaldi) can cure millions and generate tens of billions in revenue, ensuring high profitability per employee.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772676739346 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Gilead Sciences is a biopharmaceutical company specializing in antiviral drugs, particularly for the treatment of HIV and hepatitis C. Its success is based on scientific breakthroughs that have transformed the treatment of these diseases. This metric clearly illustrates how the development of revolutionary drugs generates enormous profits and makes the work of each scientist incredibly valuable.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772676739374 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Gilead Sciences Inc. (GILD)
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for the treatment of HIV and hepatitis C. This chart illustrates a model where a single successful product can generate tens of billions of dollars. The company's exceptional revenue per employee is a direct result of the commercialization of unique scientific developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Gilead-Sciences-Inc.-GILD&v=1772676739416 "Sales chart per company employee Gilead Sciences Inc. (GILD)")
Sales per employee in the market segment - Pharma virus
Gilead Sciences is a biopharmaceutical company known for its breakthrough drugs for HIV and hepatitis C, as well as (temporarily) Remdesivir. This chart shows the average revenue per employee in the segment. It demonstrates how productive their focus on virology and oncology is compared to other biotech companies.
Sales per employee for the market as a whole
Gilead Sciences is a biopharmaceutical company known for its breakthrough treatments for HIV and hepatitis C. These drugs have transformed the outlook for millions of patients. This chart demonstrates how owning patents on life-saving drugs allows the company to generate enormous revenue, recouping its R&D costs many times over.
Short shares by company, segment and market as a whole
Shares shorted by company Gilead Sciences Inc. (GILD)
Gilead Sciences is a biotech company known for its breakthrough drugs in HIV and hepatitis C treatments, including (previously) Remdesivir. The bearish sentiment seen on this chart is often associated with patent cliffs. These bears are betting that the company will be unable to offset declining revenue from its aging HIV portfolio with new developments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Gilead-Sciences-Inc.-GILD&v=1772676739477 "Short Shares Chart for the Company Gilead Sciences Inc. (GILD)")
Shares shorted by market segment - Pharma virus
Gilead Sciences is a biotech company known for its breakthroughs in HIV and hepatitis C treatments. It is currently actively developing its oncology pipeline. This chart reflects the overall sentiment in the sector. It reflects investor concerns about patent expirations on key drugs or R&D setbacks, which pose risks for the entire biotech industry.
Shares shorted by the overall market
Gilead Sciences is a biotech company known for its dominant position in HIV and hepatitis C treatments, as well as its development in oncology. This chart measures overall fear. When it rises, Gilead looks attractive. Its HIV franchise provides a stable, predictable cash flow, as patients require lifelong treatment, regardless of the economic downturn.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Gilead Sciences Inc. (GILD)
This chart shows the momentum of Gilead's stock price. For a biotech giant whose future depends on R&D, this indicator is crucial. Overbought levels (above 70) almost always indicate euphoria following successful clinical trials or the approval of a new blockbuster. A drop below 30 (oversold) often signals panic due to R&D failure or the loss of patent protection for a key drug.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Gilead-Sciences-Inc.-GILD&v=1772676739552 "RSI 14 indicator chart for the company's stock Gilead Sciences Inc. (GILD)")
RSI 14 Market Segment - Pharma virus
Gilead (GILD) is known for breakthroughs in HIV and Hepatitis C treatments. Pharmaceuticals are a risky sector, dependent on patents and clinical trial success. This chart shows whether the entire biotech segment is overbought, for example, amid pandemic news. This helps separate industry hype from Gilead's actual success in developing blockbusters.
RSI 14 for the overall market
Gilead Sciences is at the forefront of the fight against viruses, from HIV to hepatitis. This chart reflects the general euphoria or fear of investors, but Gilead's business operates by different laws—the laws of science and epidemics. Demand for its life-saving drugs is unaffected by market "temperature," making its shares a safe haven in times of panic.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GILD (Gilead Sciences Inc.)
The average target price on this chart reflects the balance of opinions on Gilead. On the one hand, analysts factor in market dominance in the HIV market (Biktarvy), which generates the bulk of their cash. On the other hand, their forecasts hinge on success in oncology (Trodelvy) and the company's ability to offset future patent cliffs. The consensus is a bet on whether the R&D pipeline can live up to expectations.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GILD-Gilead-Sciences-Inc.&v=1772676739606 "A chart showing analyst consensus forecasts for the expected stock price. GILD (Gilead Sciences Inc.)")
The difference between the consensus estimate and the actual stock price GILD (Gilead Sciences Inc.)
Gilead Sciences is a biotech company known for its breakthrough drugs for the treatment of HIV and Hepatitis C, as well as developing a pipeline in oncology. This chart shows the difference between the consensus estimate and the price. It reflects whether analysts believe the company can offset its aging franchises with new developments (particularly in oncology), seeing potential in this area.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GILD-Gilead-Sciences-Inc.&v=1772676739619 "A chart showing the difference between the consensus forecast and the actual stock price. GILD (Gilead Sciences Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Gilead Sciences is a biotech company that dominates the HIV and hepatitis C treatment markets and is now actively expanding into oncology. This chart shows analysts' overall expectations for the entire biotech sector. It reflects whether industry experts see new breakthroughs or believe the sector has exhausted its growth drivers.
Analysts' consensus forecast for the overall market share price
Gilead Sciences is a biotech giant known for breakthroughs in viral disease treatments. While the healthcare sector is often considered defensive, overall market sentiment, reflected in this chart, is still significant. Analyst optimism encourages capital flows into R&D, while pessimism can dampen risk appetite in innovative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Gilead Sciences Inc.
Gilead Sciences is a biotech leader with historical dominance in virology, particularly in the treatment of HIV and hepatitis C. Their business is a balance between stable, highly profitable HIV franchises and the pursuit of new breakthroughs, such as in oncology. This chart provides a summary assessment of their sustainability, weighing revenue from existing blockbusters against expectations for their R&D pipeline.
AKIMA Market Segment Index - Pharma virus
Gilead Sciences is a biopharmaceutical company known for its revolutionary drugs for the treatment of HIV and hepatitis C, as well as its growing oncology portfolio. This comprehensive index evaluates R&D. The chart shows the average value for the segment. It helps understand how Gilead's leadership in virology distinguishes it from the average pharma company.
The AKIM Index for the overall market
Gilead Sciences is a biotech company known for its breakthrough drugs for the treatment of HIV and hepatitis C. In recent years, the company has been actively expanding its oncology portfolio (CAR-T therapy). This chart, reflecting the market average, serves as a benchmark. It helps assess how Gilead, whose success depends on scientific innovation and the patent life cycle, compares to the overall macroeconomic trends that influence investor sentiment.
